If you are a PharmD or Clinical Pharmacy-trained pharmacist planning to practise in the Middle East, your licensing pathway will depend on the country, the professional title recognised by the regulator and the qualifications you hold. The UAE has a dedicated Clinical Pharmacy CBT, while Saudi Arabia regulates Clinical Pharmacy through a postgraduate specialty pathway and other Gulf authorities may use the general Pharmacist examination for Clinical Pharmacist applicants.
This guide covers the major Middle East health authorities and explains the eligibility requirements, exam format, syllabus, reference books and licensing pathways relevant to Clinical Pharmacy candidates.
1. What is the Clinical Pharmacy Exam?
Clinical Pharmacy assessment is designed to determine whether a pharmacist has the pharmacotherapy knowledge, patient-care skills, medication-safety awareness, pharmacokinetic competence and professional judgement required for advanced clinical pharmacy practice. There is no single Gulf-wide Clinical Pharmacy exam: the UAE publishes a dedicated Clinical Pharmacy CBT, Saudi Arabia uses a postgraduate diploma/board pathway, and Qatar, Oman, Bahrain and Kuwait apply their own pharmacist or clinical-pharmacist licensing structures.
Question type: Where a computer-based examination is required, questions are predominantly single-best-answer multiple-choice questions. The UAE Clinical Pharmacy CBT is a dedicated 150-question exam; other authorities may use a general Pharmacist exam or a postgraduate specialty assessment.
Language: English. Prometric licensing examinations covered by this guide are conducted in English.
Delivery: Mainly computer-based testing through Prometric, Pearson VUE or an authority-approved examination platform. Saudi Clinical Pharmacy specialty training also includes a final clinical examination, while Oman requires a pharmacist licensing viva in addition to its pharmacy licensing pathway.
Result: Reporting varies by regulator. The UAE Clinical Pharmacy CBT has a published percentage pass standard; Qatar and Bahrain use their published pharmacist licensure standards where the exam is required; Saudi specialty examinations follow SCFHS postgraduate assessment rules.
Attempts: Authority-specific. The UAE Unified PQR provides three examination attempts across the UAE Authorities, with limited additional-attempt provisions. Qatar currently permits five consecutive qualifying-exam attempts, while Bahrain applies its own licensure-exam attempt policy.
2. Middle East Health Authorities and Regulatory Pathways for Clinical Pharmacy
Clinical Pharmacist is not classified in exactly the same way across the Gulf. The UAE, Qatar and Bahrain explicitly recognise a Clinical Pharmacist title, Saudi Arabia has a structured Clinical Pharmacy diploma/board pathway, while Oman and Kuwait publicly regulate pharmacy through their broader pharmacist licensing systems. The table below summarises the current pathway.
Health Authority | Regulatory Pathway | Clinical Pharmacy Assessment Status |
DHA - Dubai, UAE | Clinical Pharmacist licensing under the UAE Unified PQR through DHA/Sheryan. The published Clinical Pharmacy CBT code is PHO5482. | Dedicated 150-MCQ CBT |
MOHAP - UAE | Clinical Pharmacist evaluation and licensing under the UAE Unified PQR for the Northern Emirates. | Dedicated 150-MCQ CBT |
DOH - Abu Dhabi, UAE | Clinical Pharmacist licensing through DOH/TAMM under the UAE Unified PQR. | Dedicated 150-MCQ CBT |
SCFHS - Saudi Arabia | Clinical Pharmacy is a recognised postgraduate specialty pathway. SCFHS operates the Clinical Pharmacy Diploma and Saudi Board pathway; the general SPLE is a separate pharmacist licensure exam. | Final written + clinical specialty examinations |
Oman - MOH / OMSB | OMSB lists the Omani Examination for Pharmacists (OEP) for occupational classification. Oman MOH also requires pharmacists to pass a professional-practice oral viva. A separate Clinical Pharmacist OC exam is not publicly listed. | Pharmacist pathway; no separate public Clinical Pharmacy CBT |
Qatar DHP | Clinical Pharmacist is an explicitly regulated scope. The current pharmacist guidelines distinguish qualification routes that require the Pharmacist Prometric exam from routes that are exempt. | Pharmacist Prometric when required |
NHRA - Bahrain | Clinical Pharmacist is an explicitly recognised pharmacy title under NHRA qualification requirements and is subject to the pharmacy licensure examination pathway. | Prometric pathway; no separate Clinical Pharmacy blueprint published |
Kuwait MOH | Pharmacy licensing is handled by a separate Kuwait MOH pharmacy department rather than the Medical Licensing Department. A public Clinical Pharmacy-specific exam blueprint was not verified. | Confirm current pharmacy-department assessment |
3. Clinical Pharmacy Passing Marks and Exam Format
Clinical Pharmacy examination specifications are not uniform across the Middle East. For DHA, MOHAP and DOH, the UAE Clinical Pharmacy specification is 150 MCQs in 3 hours with a 70% pass mark. Saudi Arabia uses a separate postgraduate Clinical Pharmacy specialty assessment, while Qatar and Bahrain generally apply their pharmacist licensure examination when the applicant is required to sit an exam.
Health Authority | Questions / Assessment Pattern | Duration | Pass Mark |
DHA / MOHAP / DOH - UAE | 150 MCQs · PHO5482 | 3 Hours | 70% |
SCFHS - Saudi Arabia | Clinical Pharmacy Diploma final written: 80-120 MCQs + final clinical exam | As scheduled by SCFHS | 70% standard; cannot be reduced below 65% under SCFHS rule |
Oman - OMSB / MOH | Omani Examination for Pharmacists (OEP); not a separate Clinical Pharmacy exam | Follow current OEP booklet / booking | Follow current OEP specification |
Qatar DHP | 150-MCQ Pharmacist Prometric when required | 3 Hours* | 60% |
NHRA - Bahrain | Pharmacy licensure Prometric when required; Clinical Pharmacy-specific question count not separately published | 2.5 Hours actual exam time | 60% |
Kuwait MOH | Clinical Pharmacy-specific public exam format not verified | As assigned | As assigned |
*Qatar note: the current DHP qualifying-examination webpage lists the Pharmacist examination as 150 MCQs in 3 hours with a 60% pass mark, while the 2025 National Pharmacist Qualifying Examination Blueprint labels the same 150-MCQ assessment as 3.5 hours. Clinical Pharmacists following the BPharm + PharmD route are required to provide the Prometric pass certificate, whereas the BPharm + Master’s in Clinical Pharmacy route is currently listed as exempt from Prometric. Candidates should follow their current DHP evaluation and booking instructions.
4. Eligibility Criteria for Clinical Pharmacy Candidates
Eligibility depends on the exact qualification route and on whether the regulator treats Clinical Pharmacy as a distinct title or as an advanced pharmacist scope. The UAE, Qatar and Bahrain publish explicit Clinical Pharmacist qualification routes, while Saudi Arabia uses SCFHS specialty training and classification pathways.
UAE qualification routes: The current Unified PQR recognises a PharmD / Doctor of Pharmacy of at least six years, or a BSc in Pharmacy plus a two-year postgraduate qualification leading to a PharmD / Doctor of Pharmacy or a Master’s in Clinical Pharmacy.
UAE clinical experience: The Clinical Pharmacist title generally requires at least two years of post-qualification experience in the related field in a hospital setting. A recognised Clinical Pharmacy residency of at least two years may fulfil the experience requirement under the PQR.
Saudi Clinical Pharmacy pathway: SCFHS operates a Clinical Pharmacy Diploma and Saudi Board pathway. In 2026, recognised Master’s in Clinical Pharmacy holders and recognised PGY1 Pharmacy Practice Residency holders can apply through the Clinical Pharmacy eligibility-exam route subject to SCFHS qualification review and experience requirements.
Qatar Clinical Pharmacist route: The current DHP pharmacist guideline lists BPharm + PharmD (including rotations/internship) with two years of post-graduate experience and requires Prometric; BPharm + Master’s in Clinical Pharmacy with two years of experience is listed as exempt from Prometric.
Bahrain Clinical Pharmacist route: NHRA recognises Clinical Pharmacist qualification pathways including a six-year PharmD with hospital internship/residency, DClinPharm, eligible MPharm, BSc Pharmacy plus postgraduate PharmD, or BSc Pharmacy plus a Master’s in Clinical Pharmacy. Non-Bahraini applicants generally require relevant hospital experience according to the selected route.
Professional licence and Good Standing: A valid pharmacist registration/licence and recent Certificate of Good Standing are commonly required, and the licence should support the period of professional experience claimed in the application.
Primary Source Verification: Pharmacy degrees, postgraduate Clinical Pharmacy qualifications, residency certificates, professional licences and experience may require primary-source verification such as DataFlow or another regulator-approved provider.
Clinical training documentation: Regulators may request internship or residency records, rotation details, academic transcripts, experience certificates and evidence of hospital-based clinical pharmacy practice. Saudi eligibility routes can require programme curricula, clinical-practice letters and recommendation letters.
Scope of practice: Clinical Pharmacist licensure authorises advanced medication-management activities within the regulator’s defined scope, but it does not automatically grant every subspecialty privilege. Oncology, critical care, infectious diseases, transplant, nutrition and other advanced services may require additional specialty training, facility credentialing or SCFHS board/fellowship recognition.
Examination exemption is not uniform. The UAE PQR publishes specific licensure-exam exemption criteria for eligible pharmacists and clinical pharmacists, Qatar exempts the BPharm + Master’s in Clinical Pharmacy route from Prometric under its current guideline, and other regulators apply their own assessment rules. Candidates should wait for the regulator’s evaluation before booking an examination.
5. Clinical Pharmacy Syllabus and Core Study Areas Across Middle East Health Authorities
The 14 study areas below are taken directly from the UAE Clinical Pharmacy CBT coverage and provide the core structure for this guide. Saudi Arabia’s Clinical Pharmacy Diploma final written examination places greater weight on therapeutic disease states - especially Infectious Diseases and Cardiovascular Diseases at 20% each and Acute Medical Diseases at 15% - while Qatar and Oman pharmacist exams combine clinical sciences with pharmaceutical and administrative sciences. The framework below therefore preserves the UAE domains while expanding the therapeutic content needed for broader Gulf preparation.
Topic 1: Toxicology
Principles of clinical toxicology, toxidromes, common drug and chemical poisonings, decontamination, antidotes, supportive treatment, toxicokinetics, overdose risk assessment, poison-information resources and medication-related toxicity monitoring.
Topic 2: Medicinal Chemistry
Structure-activity relationships, physicochemical properties, functional groups, stereochemistry, metabolism-related structural features and clinically relevant relationships between chemical structure, pharmacologic activity, adverse effects and drug interactions.
Topic 3: Sterile and Non-Sterile Compounding
Aseptic technique, sterile preparation principles, compatibility and stability, IV admixtures, hazardous-drug handling, non-sterile compounding, beyond-use dating, contamination prevention, quality control, calculations and safe preparation of patient-specific products.
Topic 4: Pharmaceutics and Biopharmaceutics
Dosage forms, drug-delivery systems, dissolution, absorption, bioavailability, bioequivalence, formulation factors, modified-release products, routes of administration, excipients and the clinical implications of pharmaceutical formulation.
Topic 5: Pharmacognosy and Dietary Supplements
Natural products, herbal medicines, nutraceuticals and dietary supplements; evidence for efficacy, quality and safety; common toxicities; herb-drug interactions; contraindications; product variability and counselling patients on complementary products.
Topic 6: Pharmacy Calculations and Compounding
Dose calculations, concentration and dilution, alligation, infusion rates, renal and weight-based dosing, mEq/mmol conversions, isotonicity, parenteral nutrition calculations, reconstitution, compounding mathematics and prevention of calculation-related medication errors.
Topic 7: Clinical Pharmacogenomics
Common pharmacogenomic principles, genotype-phenotype relationships, clinically actionable gene-drug pairs, interpretation of pharmacogenomic results, test limitations, implementation in medication selection/dosing and ethical considerations in genomic-guided therapy.
Topic 8: Pharmacokinetics and Therapeutic Drug Monitoring
Absorption, distribution, metabolism and elimination; clearance, volume of distribution, half-life, loading and maintenance doses, steady state, renal/hepatic adjustment, population variability and therapeutic drug monitoring for drugs with narrow therapeutic indices.
Topic 9: Pharmaceutical Care and Disease State Management
Patient-centred medication management across major disease states, including cardiovascular disease, infectious disease, endocrine/metabolic disorders, renal disease, respiratory disease, GI/hepatology, neurology/psychiatry, rheumatology, acute medical conditions, nutrition support and common chronic-care problems.
Topic 10: Medication Safety
Medication reconciliation, high-alert medicines, look-alike/sound-alike drugs, prescribing and dispensing errors, adverse drug reactions, drug interactions, error reporting, root-cause analysis, risk-reduction systems, transitions of care and safe use of medicines in vulnerable populations.
Topic 11: Over-the-Counter Medication and Self-Care
Assessment and triage of common self-limiting conditions, appropriate non-prescription medicine selection, contraindications, red flags, referral criteria, counselling, special-population considerations and prevention of duplicate or unsafe therapy.
Topic 12: Pharmacy Law, Ethics and Professional Practice
Controlled and narcotic medicine requirements, prescription validity, documentation, confidentiality, informed consent, professional boundaries, ethical decision-making, scope of practice, regulatory compliance, medication access and responsible stewardship of healthcare resources.
Topic 13: Clinical Pharmacology and Therapeutic Decision Making
Evidence-based drug selection, guideline-directed therapy, comparative efficacy and safety, dose individualisation, contraindications, drug-drug and drug-disease interactions, deprescribing, therapeutic monitoring, antimicrobial stewardship and optimisation of pharmacotherapy in complex patients.
Topic 14: Infection Control
Standard and transmission-based precautions, hand hygiene, aseptic practice, vaccination principles, infection-prevention programmes, prevention of healthcare-associated infection, antimicrobial stewardship, isolation considerations and the pharmacist’s role in safe antimicrobial use.
Cross-Authority Focus: UAE Breadth, Saudi Therapeutics and Qatar Pharmacist Core Sciences
The UAE Clinical Pharmacy CBT is unusually broad and tests both pharmaceutical sciences and advanced clinical practice. SCFHS Clinical Pharmacy final written assessment is more therapeutics-heavy: Infectious Diseases and Cardiovascular Diseases each carry 20%, Acute Medical Diseases 15%, Endocrinology/Metabolic Disorders 10%, and renal, GI/hepatology, pulmonary, neurology/psychiatry, rheumatology, nutrition and pharmacokinetics 5% each. Qatar’s national Pharmacist blueprint allocates the largest block to Clinical Sciences while still testing pharmaceutical, biomedical and administrative sciences. Strong preparation therefore requires both clinical therapeutics and the pharmaceutical-science foundation.
6. Recommended Reference Books
The UAE Clinical Pharmacy guideline lists the following core pharmacy references. Because several regulator-listed editions are older or unspecified, candidates should use the latest available editions and supplement them with current evidence-based treatment guidelines, especially for the Saudi Clinical Pharmacy therapeutic domains:
The APhA Complete Review for Pharmacy by Dick R. Gourley, James C. Eoff III and colleagues, together with the immunology foundation referenced in the UAE guideline. Broad review of pharmacy science and practice.
Lippincott Illustrated Reviews: Biochemistry, latest edition. Core biomedical and biochemical foundation relevant to pharmacology and therapeutics.
Comprehensive Pharmacy Review by Leon Shargel, Alan H. Mutnick, Paul F. Souney, Larry N. Swanson and colleagues, latest edition. Broad review across pharmaceutical and clinical sciences.
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, latest edition. Core pharmacology, mechanisms, therapeutic principles and adverse effects.
Applied Biopharmaceutics & Pharmacokinetics by Shargel and colleagues, latest edition. Core reference for biopharmaceutics, pharmacokinetics and dose individualisation.
Pharmaceutical Calculations by Howard C. Ansel and Mitchell J. Stoklosa, latest edition. Core calculations and compounding mathematics.
Aulton’s Pharmaceutics: The Design and Manufacture of Medicines, latest edition. Core pharmaceutics, dosage-form design and drug-delivery reference.
Principles of Toxicology by Karen E. Stine and Thomas M. Brown, latest edition. Foundation for toxicology and risk assessment.
Essentials of Pharmacoeconomics by Karen Rascati, latest edition. Core pharmacoeconomic and outcomes concepts relevant to formulary and therapeutic decision-making.
Current clinical practice guidelines from major bodies such as ADA, IDSA, ACC/AHA, KDIGO, GINA, GOLD, ACG/AGA, AASLD, ACR, ASPEN, AAN, AACE, CHEST, SCCM and NCCN, reflecting the disease-state guidance identified in the current SCFHS Clinical Pharmacy final-exam blueprint.
Beyond textbook study, exam-day preparation benefits from high-quality MCQ practice. The Clinical Pharmacy MCQ bank on prometricguide.com is designed around the 14-topic cross-authority framework above and includes 2500 plus questions with detailed explanations covering pharmaceutical sciences, pharmacokinetics, disease-state management, medication safety, therapeutics, law/ethics and infection control.
7. Two Ways We Can Help You Get Licensed
Prometric Guide supports Clinical Pharmacy exam preparation across the Middle East, while our sister company Alzantra International supports the UAE licensing process.
For Exam Preparation: Prometric Guide (All Middle East Authorities)
Whether you are targeting DHA, MOHAP, DOH Abu Dhabi, SCFHS Saudi Arabia, Oman, Qatar DHP, NHRA Bahrain or Kuwait MOH, our Clinical Pharmacy MCQ bank provides one broad preparation base covering the core pharmacy science and clinical knowledge shared across these pathways:
2500 plus Clinical Pharmacy MCQs mapped to the 14-topic cross-authority framework.
Detailed explanations with references to major pharmacy texts, pharmacotherapy guidelines, pharmacokinetic resources and current clinical standards.
Free introductory mock tests and topic-wise practice sets.
High-yield coverage of pharmacology, pharmaceutics, pharmacokinetics, clinical pharmacogenomics, disease-state management, medication safety, OTC care, calculations, ethics and infection control.
Access on any device, unlimited attempts.
Explore the full Clinical Pharmacy exam preparation package on prometricguide.com.
For UAE Licensing Paperwork: Alzantra International (DHA, MOHAP, DOH)
For UAE licensing, Alzantra International supports Clinical Pharmacist candidates targeting Dubai, the Northern Emirates and Abu Dhabi with documentation and licensing coordination.
DataFlow / primary-source verification of pharmacy degrees, postgraduate Clinical Pharmacy qualifications, professional licence and experience.
DHA Sheryan Clinical Pharmacist application and assessment coordination for Dubai.
MOHAP Clinical Pharmacist evaluation and licensing application for the Northern Emirates.
DOH Abu Dhabi Clinical Pharmacist application through TAMM.
Pharmacy degree, PharmD/Master’s/residency, clinical experience and supporting-document preparation guidance.
Eligibility submission, tracking and follow-up.
CBT or additional assessment coordination where required.
Clinical Pharmacist licence activation and UAE facility-credentialing support.
Contact Alzantra International at www.alzantra.ae or [email protected] for UAE licensing support. For SCFHS/Saudi Arabia, Oman, Qatar DHP, NHRA Bahrain and Kuwait MOH, follow the relevant regulator’s official pathway.
8. Frequently Asked Questions
What is the passing score for the Clinical Pharmacy exam?
For DHA, MOHAP and DOH, Clinical Pharmacy is 150 MCQs in 3 hours with a 70% pass mark. The SCFHS Clinical Pharmacy Diploma final written exam has a 70% standard pass score, with SCFHS rules allowing statistical adjustment but never below 65%. Qatar’s Pharmacist Prometric is 60% when required. Bahrain pharmacy licensure examinations use a 60% pass mark.
What qualifications are accepted for the Clinical Pharmacist title in the UAE?
The current UAE PQR recognises a six-year PharmD / Doctor of Pharmacy, or a BSc in Pharmacy plus a two-year postgraduate qualification leading to a PharmD / Doctor of Pharmacy or Master’s in Clinical Pharmacy. The title generally requires two years of related hospital experience, although an accepted two-year Clinical Pharmacy residency can fulfil the experience requirement.
How many questions are in the Clinical Pharmacy exam?
DHA, MOHAP and DOH use 150 MCQs in 3 hours. Saudi Clinical Pharmacy uses an 80-120-question final written exam plus a final clinical exam. Qatar uses the 150-question Pharmacist Prometric when required, while Oman uses the Omani Examination for Pharmacists.
Which reference books should I use?
Use the UAE-listed pharmacy references, including the APhA review, Goodman & Gilman, Shargel, Aulton's Pharmaceutics, Pharmaceutical Calculations, Principles of Toxicology and Essentials of Pharmacoeconomics, supplemented by current therapeutic guidelines.
Can I complete the exam from my home country?
Often yes when the assigned assessment is available through an international Prometric or Pearson VUE centre. Saudi postgraduate clinical examinations may require attendance according to SCFHS scheduling.
How is the SCFHS Clinical Pharmacy pathway different from the UAE exam?
Saudi Arabia uses a postgraduate Clinical Pharmacy diploma/board pathway rather than the UAE-style CBT alone. Its final written exam contains 80-120 MCQs and is followed by a final clinical examination; the general SPLE remains a separate pharmacist licensure exam.
How many attempts do I get?
Attempt limits are authority-specific. The UAE follows the Unified PQR three-attempt framework; Qatar currently permits five consecutive qualifying-exam attempts, while Bahrain and SCFHS apply their own published rules.
Does every Middle East authority use the same Clinical Pharmacy exam?
No. The UAE uses a dedicated Clinical Pharmacy CBT, Saudi Arabia uses a postgraduate specialty assessment, and Qatar, Bahrain, Oman and Kuwait follow their own pharmacist or clinical-pharmacist pathways.
Is Clinical Pharmacy the same as the general Pharmacist title?
No. Clinical Pharmacist is an advanced patient-care and pharmacotherapy scope that generally requires additional PharmD, postgraduate Clinical Pharmacy or residency training and relevant hospital experience.
What is the best MCQ bank for Clinical Pharmacy exam preparation?
The Clinical Pharmacy MCQ bank on prometricguide.com includes 2500 plus questions aligned to the 14-topic cross-authority framework, with detailed explanations across pharmaceutical sciences, pharmacokinetics, therapeutics, medication safety, law/ethics and infection control.
9. Final Thoughts
Clinical Pharmacy is an advanced pharmacy title recognised in the UAE, Qatar and Bahrain, while Saudi Arabia uses a structured postgraduate specialty pathway. Oman and Kuwait use broader pharmacy licensing routes, so candidates should confirm the exact title assigned before booking an exam.
Prepare across both pharmaceutical science and clinical therapeutics, with particular depth in pharmacokinetics, disease-state management, medication safety, therapeutic decision-making and infection control. Saudi candidates should give extra emphasis to infectious disease, cardiovascular disease and acute medical pharmacotherapy.
Prometric Guide supports Clinical Pharmacy candidates preparing across the major Middle East health authorities.